key: cord-1051389-u0d8e1do
authors: Abdelmaksoud, Ayman; Goldust, Mohamad; Vestita, Michelangelo
title: Comment on “Chronic spontaneous urticaria exacerbation in a patient with COVID‐19: rapid and excellent response to omalizumab”
date: 2020-09-29
journal: Int J Dermatol
DOI: 10.1111/ijd.15215
sha: 7ce04cee1cb13fa55ec307d772cd8509847dcf74
doc_id: 1051389
cord_uid: u0d8e1do

nan

patients were demonstrated to produce type I interferon after OMZ treatment. 6 Gill et al. 7 noticed that OMZ had restored type I interferons, namely interferon-a (IFN-a), responses to both rhinovirus and influenza. Restoring type I interferon-mediated innate immune response helps to initiate a powerful antiviral immune response 6 to inhibit SARS-CoV-2 replication, and eventually limiting dissemination of the infection at an early stage of disease. 8 Dursun et al. 9 noticed an increased rate of pityriasis rosea and Kawasaki disease in patients who presented to dermatology outpatient clinics during the COVID-19 pandemic. The authors attributed that to coronavirus triggering of HHV-6 (i.e. endogenous viral reactivation of HHV-6 by SARS-CoV-2 infection). Dreyfus observed that HHV-6 reactivation and gene expression could play a role in CSU pathogenesis in OMZ-dependent CSU who had evidence of past infection with HHV-6 and serology. 10 Dreyfus thought that long-term OMZ therapy may be required to decrease HHV-6 titers. 10 Interestingly, OMZ has been used safely for CSU continuously for up to 25 months, according to a recent study from Turkey. 11 An antiviral potential of OMZ may stand behind its mechanism of action in treatment of respiratory viral infections, including SARS-CoV-2, and secondary activated endogenous viruses, such as HHV-6, that are involved in the pathogenesis of CSU or chronic viral urticaria. 7, 9, 10 Garc ıa-Gil et al. 12 

Urticaria in the times of COVID-19

Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab

Omalizumab and COVID-19 treatment: could it help?

What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?

Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab

Antiviral activities of type I interferons to SARS-CoV-2 infection

The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease

Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/ spontaneous urticaria (CIU)

Long-term follow-up effect of omalizumab in chronic spontaneous urticaria and its association with serum C-reactive protein levels

Acroischemic lesions associated with extremely elevated D-Dimer in a child during the COVID-19 pandemic

COVID-19-related cutaneous manifestations associated with multiple drug sensitization as shown by lymphocyte transformation test

Enanthem in patients with COVID-19 and skin rash